{
    "Trade/Device Name(s)": [
        "BD Phoenix Automated Microbiology System",
        "BD PhoenixM Automated Microbiology System",
        "BD PhoenixM Automated Microbiology System for use with the antimicrobial agent cefazolin (2-32 \u03bcg/mL) - Gram positive ID/AST or AST only Phoenix panels"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K050555",
    "Predicate Device Reference 510(k) Number(s)": [
        "N50510",
        "K020321",
        "K020323",
        "K020322"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "April 14, 2005",
    "Summary Letter Received Date": "March 3, 2005",
    "Submission Date": "March 1, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Cefazolin"
    ],
    "Specimen Type(s)": [
        "Pure culture isolates of Gram-negative aerobic and facultative anaerobic bacteria",
        "Pure culture isolates of Gram-positive bacteria (Staphylococcus and Enterococcus)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Automated broth microdilution",
        "Redox indicator detection"
    ],
    "Methodologies": [
        "Minimum inhibitory concentration determination",
        "Antimicrobial susceptibility testing"
    ],
    "Submission Type(s)": [
        "System",
        "Panel",
        "Reagent",
        "Instrument",
        "Software",
        "Broth"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix Automated Microbiology System incorporating cefazolin (2-32 \u03bcg/mL) for antimicrobial susceptibility testing of Gram-positive and Gram-negative bacteria",
    "Indications for Use Summary": "For rapid identification and in vitro antimicrobial susceptibility testing by MIC determination of isolates from pure culture of aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria of human origin, including Staphylococcus and Enterococcus, using panels containing cefazolin at 2-32 \u03bcg/mL",
    "fda_folder": "Microbiology"
}